CM
CLDX icon

Caption Management’s Celldex Therapeutics CLDX Stock Holding History

Caption Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25,000
Closed -$850K – 1500
2024
Q3 		$850K Buy
+25,000
New +$953K 0.01% 819
2024
Q1 		– Sell
-176,100
Closed -$6.98M – 1265
2023
Q4 		$6.98M Buy
176,100
+76,100
+76% +$2.24M 0.09% 253
2023
Q3 		$2.75M Buy
+100,000
New +$3.13M 0.04% 501
2022
Q3 		– Sell
-151,200
Closed -$4.08M – 1541
2022
Q2 		$4.08M Buy
+151,200
New +$4.39M 0.06% 425
2021
Q3 		– Sell
-113,800
Closed -$3.81M – 1538
2021
Q2 		$3.81M Buy
+113,800
New +$3.12M 0.05% 449

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return